Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Life at Takeda
Design Concept
Where we work
Corporate Philosophy
Our People
Values and Corporate Governance
Corporate Governance
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
From the CEO
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Investigator Initiated Research
Takeda Ventures, Inc.
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Partnering with Takeda
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
Takeda Supplier Solutions Portal
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Project members
Inside T-CiRA
Research Achievements
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Quality at Takeda
The Key Elements at the Heart of Our Innovation
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
Caring
Medicine for the World
Safeguarding Plant Diversity
Takeda at TICAD6
Going Beyond Medicines
Change the World
Healthcare for All
Shared Knowledge for a Better Life for All
Harnessing the Power of People to Transform Health Care
Improving Access to Healthcare in Remote Communities
Shifting paradigms of COVID-19 reflections from the 75th UN General Assembly
Heritage
Keys to Aging Gracefully
Harnessing the power of people to transform health care
LEARN MORE
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Frequently Asked Questions
Leaders Driving Change
Sustainable Value Report
Human Rights
Labor
Environment
Commitment to Carbon Neutrality
Emission Reduction Targets
Anti-Corruption
TAKEDA LIFE THEATER
Partner with our Global CSR Program
LEARN MORE
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Message from the CEO
News Releases
Enter
All
Last 12 months
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
January 2021
January 11, 2021
1/11/2021
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50 percent by FY2030 at the 39th Annual JP Morgan Healthcare Conference
January 11, 2021
1/11/2021
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
1/5/2021
Takeda Completes Sale of Select Non-Core Assets to Cheplapharm
December 2020
December 21, 2020
12/21/2020
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
December 18, 2020
12/18/2020
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
December 15, 2020
12/15/2020
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
December 9, 2020
12/9/2020
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
December 8, 2020
12/8/2020
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
December 7, 2020
12/7/2020
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
1
2
3
4
5
TOP